KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-Current Deffered Revenue: 2019-2022

Historic Non-Current Deffered Revenue for Esperion Therapeutics (ESPR) over the last 1 years, with Jun 2022 value amounting to $211,000.

  • Esperion Therapeutics' Non-Current Deffered Revenue fell 80.04% to $211,000 in Q2 2022 from the same period last year, while for Jun 2022 it was $211,000, marking a year-over-year decrease of 80.04%. This contributed to the annual value of $634,000 for FY2021, which is N/A change from last year.
  • As of Q2 2022, Esperion Therapeutics' Non-Current Deffered Revenue stood at $211,000, which was down 50.00% from $422,000 recorded in Q1 2022.
  • Esperion Therapeutics' 5-year Non-Current Deffered Revenue high stood at $1.1 million for Q2 2021, and its period low was $211,000 during Q2 2022.
  • For the 2-year period, Esperion Therapeutics' Non-Current Deffered Revenue averaged around $633,800, with its median value being $634,000 (2021).
  • Data for Esperion Therapeutics' Non-Current Deffered Revenue shows a maximum YoY tumbled of 80.04% (in 2022) over the last 5 years.
  • Esperion Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $655,000 in 2019, then reached $634,000 in 2021, then crashed by 80.04% to $211,000 in 2022.
  • Its Non-Current Deffered Revenue was $211,000 in Q2 2022, compared to $422,000 in Q1 2022 and $634,000 in Q4 2021.